Coherus BioSciences, Inc. financial data

Symbol
CHRS on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
C/O Dennis M. Lanfear, 333 Twin Dolphin Dr, Suite 600, Redwood City, California
State of incorporation
Delaware
Fiscal year end
December 31
Former names
BioGenerics, Inc. (to 1/3/2012)
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 134 % -47.3%
Quick Ratio 16.1 % -46%
Debt-to-equity -638 % -54%
Return On Assets -4.43 % +92%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 115M shares +22%
Common Stock, Shares, Outstanding 115M shares +22%
Entity Public Float 324M USD -26.9%
Common Stock, Value, Issued 12K USD +33.3%
Weighted Average Number of Shares Outstanding, Basic 115M shares +31.6%
Weighted Average Number of Shares Outstanding, Diluted 115M shares +31.6%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 102M USD -22.5%
Costs and Expenses 472M USD +13.4%
Operating Income (Loss) -164M USD +30%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -29.7M USD +88.7%
Income Tax Expense (Benefit) -380K USD
Net Income (Loss) Attributable to Parent -29.3M USD +88.9%
Earnings Per Share, Basic -0.28 USD/shares +91.6%
Earnings Per Share, Diluted -0.36 USD/shares +89.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 159M USD +118%
Marketable Securities, Current 14.9M USD -88.4%
Inventory, Net 62.2M USD -2.86%
Assets, Current 558M USD +44.7%
Property, Plant and Equipment, Net 3.33M USD -51.9%
Operating Lease, Right-of-Use Asset 5.91M USD +3.9%
Intangible Assets, Net (Excluding Goodwill) 71.7M USD +1108%
Goodwill 943K USD 0%
Other Assets, Noncurrent 8.26M USD +9.74%
Assets 675M USD +43.7%
Accounts Payable, Current 76.8M USD +162%
Employee-related Liabilities, Current 14.2M USD +0.1%
Accrued Liabilities, Current 61M USD +46%
Liabilities, Current 463M USD +173%
Deferred Income Tax Liabilities, Net 1.1M USD
Operating Lease, Liability, Noncurrent 4.98M USD +37.2%
Other Liabilities, Noncurrent 27.7M USD +27054%
Liabilities 759M USD +17.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax -272K USD +8.42%
Retained Earnings (Accumulated Deficit) -1.49B USD -2.01%
Stockholders' Equity Attributable to Parent -84.1M USD +51.9%
Liabilities and Equity 675M USD +43.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -46.8M USD +32%
Net Cash Provided by (Used in) Financing Activities 887K USD -76.7%
Net Cash Provided by (Used in) Investing Activities 203M USD +1057%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 115M shares +22%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 157M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 160M USD +118%
Deferred Tax Assets, Valuation Allowance 423M USD +25.3%
Deferred Tax Assets, Gross 430M USD +26.4%
Operating Lease, Liability 6.4M USD -5.24%
Payments to Acquire Property, Plant, and Equipment 152K USD -75.3%
Lessee, Operating Lease, Liability, to be Paid 7.94M USD +7.32%
Operating Lease, Liability, Current 1.42M USD -54.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.19M USD -27.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.1M USD -41.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure +50%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.54M USD +138%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.13M USD +416%
Deferred Tax Assets, Operating Loss Carryforwards 170M USD +29.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares
Unrecognized Tax Benefits 17.4M USD +3.44%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.53M USD +424%
Additional Paid in Capital 1.41B USD +9.33%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 700K USD
Depreciation, Depletion and Amortization 2.6M USD -37.5%
Share-based Payment Arrangement, Expense 7.23M USD -28.2%
Interest Expense 37.3M USD +2.07%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares